Overview
Bio Protocol (formerly Bio.xyz) is a decentralized funding, governance and liquidity engine for early-stage science — a protocol for directing capital and talent to biotech DAOs ("BioDAOs") and tokenized scientific IP. It incubates and funds specialized BioDAOs, each focused on a specific disease area or scientific domain.
The platform raised over $33 million through Bio Genesis in November 2024, with Binance Labs making its first DeSci investment. In June 2026 it introduced OpenLabs, an AI research hub unveiled at DeSci.Berlin 2026 that folds idea development, contributor coordination and funding into a single interface. Bio Protocol runs the tokenization layer built on Molecule.
BIO, veBIO and BioXP under Bio Protocol V2
BIO is the protocol's native token, with a capped maximum supply of 3.32 billion. Its allocation is weighted toward the ecosystem it funds: roughly 34.9% to ecosystem incentives, 25% core contributors, 13.6% investors, 10.5% protocol treasury, 8% community auctions and 8% BioDAO incentives.
Bio Protocol V2 changed what that token does. The earlier design asked BIO holders to stake on the BioDAOs they wanted admitted, making the token a curation gate on the pipeline. V2 replaced that with two launch tracks: Community Launches, a permissionless track where any team meeting the launchpad's baseline criteria can launch on a standard template, and Curated Launches, a higher-touch track Bio selects into with bespoke tokenomics and post-launch market support. Admission to the permissionless track is no longer something token holders vote or stake a project through.
What the token buys instead is priority. Every launch runs as an Ignition Sale: a fixed price, the same for all participants, denominated in USDC, all-or-nothing against a predefined raise goal – if the goal is not met, every committed dollar is returned. The sales are open to anyone with USDC and carry no BioXP gate; BioXP only decides who gets what when a sale is oversubscribed. A contributor who pledges no BioXP is counted as having pledged 1, the lowest priority weight.
veBIO: a vote-escrow lock that does not yet vote
Staking BIO mints veBIO, a vote-escrowed balance. The lock runs from one week to two years and the weight is veBIO per BIO = weeks remaining in lock / 104, decaying linearly toward the unlock date unless auto-renewal is left on. BIO cannot be withdrawn before the lock expires, and veBIO staking launched on Base only.
The notable detail for anyone reading this as a governance design: veBIO does not currently govern anything. Bio's own documentation states that BIO and vBIO remain the governance tokens of the protocol until veBIO gains sufficient adoption and a formal governance proposal is passed. The escrow is live and accruing benefits while the voting right it is named for is still pending a vote.
What veBIO does confer today is airdrop exposure. Every new token launched on the platform allocates a share of supply to veBIO holders, distributed pro-rata with no cap and unlocking on an rEUL-style curve: 20% redeemable at TGE, the remaining 80% linearly over six months. Redeeming early permanently forfeits the still-locked remainder of that allocation, which is burned from supply.
BioXP
BioXP is the points layer that sets allocation priority. It is earned by staking BIO, by staking ecosystem assets (IP Tokens, BioAgent tokens and BioDAO tokens), or minted on demand at $0.01 per XP, paid in BIO. Points from BIO staking are credited automatically each day; points from ecosystem-token staking must be claimed manually each day or they expire the next. All BioXP expires 14 days after issue, which Bio describes as a deliberate check on concentration.
Staking an ecosystem token is the looser of the two: no lock duration, but a two-week unstaking cooldown during which points stop accruing immediately, and it yields no vote-escrow token of any kind. BioDAO tokens staked on Base include VITA, HAIR, NEURON, PSY, ATH, CRYO and GROW.
Read as DAO tokenomics, V2 is a deliberate retreat from governance-by-token toward access-by-commitment: the token no longer decides which science gets funded, it decides who gets to the front of the queue when the market wants in.
The Liquidity Engine
The Liquidity Engine is the part of V2 that decides how a funded project keeps getting paid, and it is the clearest break from the one-off treasury raise that most DAOs launched on. Three mechanisms run together.
- Automatic pool seeding. A successful Ignition Sale immediately creates a liquidity pool for the new token. For a standard agent launch, all USDC raised is paired against the token, which accounts for 37.5% of supply. If the project later hits its milestones, a BIO/token pool is added alongside. This is protocol-owned liquidity created at launch rather than rented with emissions.
- Limit-sell fundraising. A reserved share of supply is not handed over at launch. Concentrated liquidity is placed at pre-set fully-diluted-valuation milestones, functioning as standing sell limit orders, and the proceeds unlock to the team only once the token reaches and holds that level for two weeks. Funding tracks sustained market traction rather than launch-day enthusiasm.
- Secondary-market fees. A 1% fee applies to every buy and every sell of the project's token, split 70% to the project treasury and 30% to Bio Protocol. For the project this is continuous non-dilutive revenue; for the protocol it is a claim on the trading volume of everything it launches.
The design has an obvious edge. Tying a team's funding to a two-week-sustained valuation makes the treasury a function of the token chart, which is exactly the coupling AthenaBIO moved away from when it routed institutional capital through an equity vehicle instead, on the reasoning that a freely-traded token price never reflects the value of the underlying science. Bio's answer is not to decouple the two but to make the coupling explicit and milestone-gated.
BioDAO ecosystem
Bio Protocol's own ecosystem listing carried ten BioDAOs when read on 25 August 2026 – the same ten as in the Internet Archive's 12 June 2026 capture. The eleventh below, DermaLabs, came off the same launchpad – its $SKIN Ignition Sale ran in December 2025 and Bio published its own February 2026 profile of it – but appears in neither capture of that listing, so a count taken off the listing and a count taken off the launchpad's own history do not agree. The BioAgents in the next section are counted separately: they hold a token and a treasury but no voting membership.
- VitaDAO — longevity research (initiated July 2021)
- AthenaBIO — women's health
- PsyDAO — psychedelic science
- ValleyDAO — synthetic biology
- HairDAO — hair-loss research (patents its DAO-funded findings)
- CryoDAO — cryopreservation
- Cerebrum DAO — brain health
- Curetopia — rare diseases
- Long COVID Labs — Long COVID research
- Quantum Biology DAO — quantum biology
- DermaLabs — skincare science
BioAgents
From 2026 the same Launcher also issues BioAgents — autonomous research agents that hold a token and a treasury without a voting membership. Aubrai came first; PeptAI is the one that has published wet-lab confirmation of an agent-designed candidate, and its May 2026 Ignition Sale is the reference example of the mechanism described above.
How Caper approaches this
Bio Protocol is a launchpad: a shared curation-and-funding layer that stands up many BioDAOs, each of which then needs its own token, treasury and governance. A caper is the opposite shape — a single self-contained primitive where the fundraise (a bonding curve), the treasury, the proposal system (PAYOUT / INVEST / DIVEST / VOTE) and a participation-weighted exit ship together. The two are complementary: an ecosystem curator answers "which projects deserve capital"; a caper answers "how does one funded community raise, spend and let members leave without stitching four tools together."